07:00 , May 12, 2014 |  BioCentury  |  Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Spreading six

Abingworth's sixth flagship fund likely will put more money towards the opposite ends of the firm's investment universe - start-ups and public companies. The new fund closed last week at £225 million ($375 million). Seven...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Crealta Pharmaceuticals Inc., GTCR LLC pharmaceuticals news

Crealta debuted last week as the second partnership between Ed Fiorentino and private equity firm GTCR, which may invest up to $200 million in the newco. Crealta will focus on acquiring specialty pharmaceutical companies and...
07:00 , Aug 5, 2013 |  BioCentury  |  Finance

Deciphering Dicerna's future

Dicerna Pharmaceuticals Inc .'s $60 million series C round last week attracted a syndicate of crossover investors that could usher the second-generation RNAi play to a public listing by this time next year. New investor...
07:00 , Jun 10, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Actient, Auxilium deal

Auxilium acquired urology company Actient for $585 million in cash up front, plus warrants and up to $50 million in revenue-dependent milestones. Actient shareholders also will receive warrants for 1.3 million shares of Auxilium stock...
07:00 , May 6, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) fell $0.77 to $7.63 on Friday's news it is withdrawing an MAA from EMA for obesity drug Belviq lorcaserin to gain more feedback on the application from CHMP. In...
07:00 , May 6, 2013 |  BioCentury  |  Finance

Perpetual acceleration

Harvard University...
00:49 , Apr 30, 2013 |  BC Extra  |  Financial News

Auxilium slips on 1Q13 results, Actient acquisition

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) fell $2.03 (13%) to $14 on Monday after reporting 1Q13 revenues that missed the Street and disclosing it acquired urology company Actient Pharmaceuticals LLC (Lake Forest, Ill.) for $585 million in...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

Columbia Laboratories, Invaron Pharmaceuticals sales and marketing update

Columbia granted Invaron Canadian commercialization rights to Striant testosterone buccal system. The buccal testosterone tablets are approved in the U.S. for testosterone replacement therapy in men for conditions associated with a deficiency or absence of...